Glioblastoma remains among the deadliest brain tumors, with survival times varying widely among patients, complicating therapeutic decision-making. Despite improvements in therapy, precision in predicting patient prognosis has lagged behind, largely due to the heterogeneous nature of the tumor. The 2021 World Health Organization classification recognizes this heterogeneity, particularly highlighting the IDH-wt subtype, which lacks targeted molecular therapies and exhibits variable progression rates.

The research team retrospectively studied a cohort of 369 IDH-wt GBM patients. This sizable dataset included 273 patients from three hospitals, divided into training and testing groups, and 96 patients from The Cancer Imaging Archive (TCIA) serving as an independent validation set. Such comprehensive data pooling is rare and critical for developing robust models that generalize well across different clinical populations and imaging protocols.

Central to their methodology was the extraction of radiomics features from both the tumor core and the surrounding peritumoral edema visible on preoperative contrast-enhanced T1-weighted MRI (CE-T1WI) and T2-weighted fluid-attenuated inversion recovery (T2 FLAIR) sequences. Radiomics involves the transformation of medical images into high-dimensional data, capturing subtle textural and spatial patterns that are inaccessible to the naked eye but potentially reflect underlying pathophysiology.

Through rigorous statistical analyses including univariate screening and least absolute shrinkage and selection operator (LASSO) Cox regression, the investigators distilled numerous radiomics features into a refined radiomics-based prognostic model. This model was capable of categorizing patients into distinct high-risk and low-risk groups according to their predicted survival, demonstrating strikingly higher performance metrics than traditional clinical models that rely on well-known risk factors alone.

The clinical risk model, based on conventional clinical variables and patient demographics, showed moderate predictive ability; however, the radiomics model consistently outperformed it across training, testing, and validation cohorts, with concordance indexes (C-index) ranging from 0.69 to 0.76. The combined model, which integrated both radiomics and clinical features using an advanced machine learning technique known as Random Survival Forests, yielded the best predictive accuracy, pushing C-index values up to nearly 0.79 in the training set.

Remarkably, this combined model represented an approximate 12.57% improvement in survival stratification capability over the clinical model, underscoring the additive value of incorporating quantitative imaging biomarkers. This improvement holds the potential to significantly impact clinical decision-making, allowing clinicians to better tailor treatment regimens based on individualized risk profiles.

Beyond mere prognostication, the study also ventured into the biological underpinnings of the radiomics findings. By examining differential gene expression between molecularly defined high-risk and low-risk groups identified by the combined model, the researchers uncovered compelling evidence linking the activation of Gamma-aminobutyric acid (GABA) receptor-related pathways with aggressive tumor behavior and poorer outcomes.

GABA, best known as a central nervous system inhibitory neurotransmitter, has increasingly been recognized for its role in cancer biology, influencing tumor cell proliferation, migration, and interaction with the tumor microenvironment. The activation of GABA receptor pathways in high-risk glioblastomas could open new avenues for therapeutic targeting, shifting the paradigm toward receptor modulation alongside traditional oncologic therapies.

This intersection of imaging phenotypes with underlying molecular biology enhances our understanding of glioblastoma heterogeneity and reinforces the potential for radiogenomics—a fusion of radiomics and genomics—to revolutionize personalized oncology. The approach circumvents the need for invasive tissue sampling while generating actionable insights driving precision medicine.

Importantly, the study’s design utilizing multiple independent datasets strengthens confidence in the generalizability of their findings. The use of standardized MRI sequences and thorough validation minimizes biases commonly seen in retrospective imaging biomarker research, hence supporting potential future clinical implementation.

While the study focused on newly classified WHO 2021 criteria IDH-wt GBM, its methodologies could be readily extended to other molecularly distinct brain tumor subtypes and even beyond neuro-oncology. Leveraging radiomics for survival prediction may ultimately transform how clinicians assess tumor aggressiveness, monitor disease progression, and optimize patient-specific therapeutic choices.

As artificial intelligence and machine learning techniques continue to evolve and integrate with clinical workflows, this convergence exemplified by the combined radiomics-biological model marks a crucial step toward truly individualized cancer care. It opens exciting prospects for real-time, noninvasive tumor characterization that can adapt dynamically as tumor biology changes.

Nevertheless, translating these findings into routine clinical practice will require further prospective studies and real-world validation to assess utility, cost-effectiveness, and workflow integration. Prospective clinical trials assessing treatment response predicated on radiomics risk stratification could solidify clinical adoption.

To summarize, this landmark research not only introduces a novel survival risk stratification tool rooted in cutting-edge MRI radiomics and biological exploration but also highlights key molecular pathways amenable to future therapeutic innovation. It sets a new standard for prognostic modeling in IDH-wt glioblastoma and exemplifies the promise of precision neuro-oncology in the era of data-driven medicine.

Subject of Research: Survival risk stratification in 2021 WHO isocitrate dehydrogenase wild type glioblastoma using MRI radiomics and biological pathway analysis.

Article Title: Survival risk stratification of 2021 WHO glioblastoma by MRI radiomics and biological exploration.

Article References:
Li, Y., Xu, W., Zhao, C. et al. Survival risk stratification of 2021 WHO glioblastoma by MRI radiomics and biological exploration. BMC Cancer 25, 1505 (2025). https://doi.org/10.1186/s12885-025-14906-2

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14906-2

Glioblastoma remains one of the deadliest and most refractory tumors, with median survival barely exceeding a year despite aggressive treatments. Tumor heterogeneity, adaptive resistance mechanisms, and a highly immunosuppressive microenvironment contribute to its resilience. Recent cancer research has increasingly focused on exploiting cell death modalities such as pyroptosis to overcome resistance and sensitize tumors to therapy. GSDME stands out among gasdermin family members for its canonical role as a pyroptotic executor, typically activated downstream of caspase-3, enabling membrane pore formation and consequent inflammatory cell lysis.

The newly published work, led by Solel et al., ventures deep into how glioblastoma cells manipulate GSDME function to evade pyroptotic demise. The study provides compelling evidence that glioblastoma cells not only resist GSDME-mediated pyroptosis but paradoxically utilize GSDME to enhance malignant behaviors including proliferation, migration, and immune evasion. This reshapes GSDME from a straightforward tumor suppressor into a multifaceted contributor to tumor fitness—a revelation with profound implications for therapeutic strategies targeting programmed cell death pathways.

Mechanistically, the researchers demonstrated that glioblastoma cells exhibit altered post-translational modifications and spatial distribution of GSDME, preventing canonical cleavage events that would trigger pyroptosis. Instead, GSDME predominantly localizes in subcellular compartments associated with tumorigenic signaling cascades, maintaining cell viability while fostering oncogenic phenotypes. This subversion of a conventional death effector underscores the ingenuity of glioblastoma’s survival arsenal and suggests that attempts to pharmacologically augment GSDME-induced pyroptosis could face unexpected pitfalls.

The interplay between GSDME and the tumor microenvironment also emerged as a critical axis shaping glioblastoma progression. Resistant glioblastoma cells, through GSDME-dependent mechanisms, appear to modulate immune cell recruitment and activation, contributing to the immune-escape characteristic of these tumors. By dampening inflammatory signals typically unleashed during pyroptosis, glioblastoma modifies immune landscape to its advantage, fostering an environment conducive to tumor growth and therapy resistance.

Importantly, the study utilises a combination of in vitro glioblastoma models, patient-derived cells, and in vivo murine systems to validate these findings. This multifaceted approach ensures robustness of the conclusions and provides a translational backbone emphasizing the clinical relevance of targeting GSDME pathways. The authors discuss the nuance required in therapeutic design, suggesting that overcoming GSDME’s tumor-promoting functions may necessitate interventions beyond simple activation of pyroptosis triggers.

The revelation that GSDME functions diverge dramatically between cancer types adds an additional layer of complexity. While in several cancers GSDME activation corresponds with enhanced cell death and better clinical outcomes, glioblastoma inverts this relationship. Such context-dependent functional plasticity mandates cancer-specific explorations before generalizing gasdermin-targeted approaches, highlighting the need for precision oncology frameworks tailored to molecular and microenvironmental tumor landscapes.

In describing the molecular underpinnings, the authors identify critical post-translational modifiers, including phosphorylation sites and interacting partners, that attenuate GSDME’s pore-forming activity in glioblastoma cells. These modifications appear to be orchestrated by oncogenic signaling nodes frequently dysregulated in glioblastoma, such as the PI3K/AKT and MAPK pathways. This integrative signaling crosstalk positions GSDME as a nexus where cell death resistance and pro-tumoral signaling converge, pinpointing novel targets for combination therapies.

Furthermore, the study delves into how GSDME influences cellular metabolism and stress response pathways. Glioblastoma cells leverage GSDME to sustain metabolic flexibility in hostile microenvironments characterized by hypoxia and nutrient deprivation. This metabolic support role stands in stark contrast to the enzyme’s canonical pyroptotic function and demonstrates the evolutionary adaptability of cancer cells to repurpose death effectors for survival advantages.

Equally striking is the finding that GSDME expression levels correlate with poor prognosis in glioblastoma patients, as shown through rigorous bioinformatic analyses of clinical datasets. High GSDME expression associates with aggressive molecular subtypes, resistance to standard of care therapies, and diminished overall survival, suggesting its potential utility as a prognostic biomarker. This clinical linkage provides a compelling rationale for the development of GSDME-targeted diagnostics and therapeutics.

Notably, the research team also explored experimental approaches to reverse pyroptosis resistance by manipulating GSDME cleavage independently of endogenous regulatory hurdles. While pharmacologic or genetic activation of caspase-3 cleavage sites restored some pyroptotic sensitivity, glioblastoma cells compensated by invoking alternative survival pathways, underscoring the robustness of tumor adaptive mechanisms. These findings advocate for combinatorial strategies that simultaneously dismantle compensatory circuits alongside pyroptosis induction.

Insights from this investigation force a reevaluation of gasdermins as universal death effectors and call for nuanced frameworks appreciating their multifaceted roles in tumor biology. For glioblastoma, the dual identity of GSDME as both a potential tumor suppressor and a promoter of tumor progression exemplifies the complexity of programmed cell death regulation within malignancies with high adaptability and plasticity.

The implications of this work extend beyond glioblastoma. Other cancers with low pyroptotic responsiveness may similarly exploit gasdermin family member functions for survival and progression, highlighting a broader biological principle. Future research will need to dissect these context-specific roles and develop therapeutics capable of modulating gasdermin activity with precision, either restoring their death effector functions or mitigating their tumor-supportive roles.

In conclusion, Solel and colleagues have illuminated a counterintuitive yet mechanistically coherent paradigm wherein Gasdermin E, a protein classically associated with inflammatory cell death, imparts survival advantages and pro-tumoral functionalities in glioblastoma. This dualistic behavior reframes therapeutic targeting strategies, advocating for a more intricate understanding of programmed cell death machinery in glioblastoma and possibly other refractory cancers. As the field advances, harnessing or inhibiting GSDME’s multifaceted roles may become a cornerstone in developing next-generation glioblastoma therapies aiming to overcome the formidable barriers posed by this devastating disease.

Subject of Research:
Gasdermin E’s role in glioblastoma, focusing on pyroptosis resistance and tumor-promoting functions.

Article Title:
Gasdermin E in glioblastoma – pyroptosis resistance and tumor-promoting functions.

Article References:
Solel, E., Brudvik, E., Ystaas, L.A.R. et al. Gasdermin E in glioblastoma – pyroptosis resistance and tumor-promoting functions. Cell Death Discov. 11, 284 (2025). https://doi.org/10.1038/s41420-025-02572-z

Image Credits:
AI Generated

DOI:
https://doi.org/10.1038/s41420-025-02572-z